ERBB3 and lung carcinoma: Further research may be able to identify predictive biomarkers for responses to anti-HER3 therapy and explore other agents such as an emerging anti-HER3 antibody-drug conjugate, U3-1402, which has shown anti-tumour activity in breast and lung cancer [202,203].